Navigation Links
Uroplasty To Participate In Two Upcoming Investor Conferences
Date:11/6/2012

MINNEAPOLIS, Nov. 6, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in two upcoming investor conferences in November – the Stephens Fall Investment Conference and the Lazard 9th Annual Healthcare Conference. Detailed information is provided below:What:

Stephens Fall Investment ConferenceWhere:

New York Palace Hotel, New York, NYDate:

Tuesday, November 13, 2012Time:

4:00 pm ET 

What:

Lazard 9th Annual Healthcare ConferenceWhere:

Pierre Hotel, New York, NYDate:

Wednesday, November 14, 2012Time:

11:00 am ETDavid Kaysen, President and CEO, and Medi Jiwani, Chief Financial Officer, will discuss recent financial results and current corporate developments at both conferences.

Uroplasty will offer a live audio webcast of both events on the Company's website, www.uroplasty.com, under Investor Information. An archived replay of the presentation will be available for 30 days, also at www.uroplasty.com.

About Uroplasty, Inc.Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-bas
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
2. Uroplasty Announces Product Development and New Clinical Trial Initiatives
3. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2012 Financial Results
4. Uroplasty To Present At The JMP Securities Healthcare Conference
5. Uroplasty to Issue First Quarter of Fiscal 2013 Financial Results on July 26, 2012
6. Uroplasty Reports Fiscal First Quarter 2013 Financial Results
7. Uroplasty To Participate In Two Upcoming Conferences
8. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
9. WAISMANN METHOD® Director Encourages Public to Participate in National Take-Back Day
10. Hill-Rom to Participate in the Deutsche Bank Securities Health Care Conference
11. Hill-Rom to Participate in the Bank of America Merrill Lynch 2012 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Most osteoporosis patients want a choice in ... survey* sponsored by Mission Pharmacal Company. The survey, conducted ... online support community, revealed that 74 percent of osteoporosis ... a form other than a pill or a tablet. ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Phase III Studies With Ofatumumab, Zalutumumab and Zanolimumab, ... (OMX:,GEN) reports today that the last patient to ... in the pivotal Phase III clinical trial,of ofatumumab ... received the last scheduled treatment., In order ...
... Company to Host Conference Call/Webcast at 8:30 a.m. ... May 28 Alfacell Corporation,(Nasdaq: ACEL ) ... from its confirmatory Phase IIIb clinical trial of ... significance for the,primary endpoint of survival in unresectable ...
Cached Medicine Technology:Genmab Announces Updates on Phase III Cancer Studies 2Genmab Announces Updates on Phase III Cancer Studies 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 2Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 3Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 4Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial 5
(Date:7/9/2014)... been a sharp increase in the number of cancer ... online, interactive service that allows patients to view laboratory ... appointments, and renew prescriptions. , Over a six-year period, ... each year increased five-fold, while the number of total ... a study by Dr. David Gerber , Associate ...
(Date:7/9/2014)... of flatulence and have a reputation for being highly toxic, ... is now being being found to offer potential health benefits ... attacks and dementia. A new compound (AP39), designed and made ... future therapies, by targeting delivery of very small amounts of ... , Scientists in Exeter have already found that the ...
(Date:7/9/2014)... printing on prescription labels handed out by pharmacists ... in taking medication, according to new research by ... Institute for the Blind)., The study, published recently ... that labels on prescription medications dispensed by pharmacies ... legibility. , By simply following recommended guidelines for ...
(Date:7/9/2014)... diseases has risen dramatically in Western societies. One frequently ... microorganisms and have fewer infections than previous generations, thereby ... by researchers at Sahlgrenska Academy, University of Gothenburg, monitored ... of the immune system in relation to allergic disease. ... the Vstra Gtaland Region, half of them on farms ...
(Date:7/8/2014)... Defense Advanced Research Projects Agency (DARPA) awarded Lawrence ... to develop an implantable neural device with the ... brain to help restore memory, DARPA officials announced ... understanding that memory is a process in which ... information, store it and retrieve it. Certain types ...
Breaking Medicine News(10 mins):Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Most prescription labels fail to meet guidelines, risking dosage errors 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 2Health News:DARPA selects Lawrence Livermore to develop world's first neural device to restore memory 3
... Calif., March 10 ISTA Pharmaceuticals, Inc. (Nasdaq: ... the Cowen and Company 29th Annual Health Care Conference ... 2009, in Boston, MA.ISTA,s President and Chief Executive Officer, ... the Company,s commercial and clinical progress. To access the ...
... 10 Orthocrat, Ltd. announced today that OAD ... OrthoFlow workflow solution. OrthoFlow is designed to save ... exam room to exam room, seeing large volumes of patients ... simply swipes his badge over a reader, and the images ...
... Sahlgrenska Academy, University of Gothenburg, Sweden, shows that three genes ... normally involved in several fundamental processes in the cell. This ... life and principally affect children and young people. , A ... investigated in the work presented in the thesis. This family ...
... Waterlase(TM), DIAGNOdent Laser Technology and the First Comprehensive Dental ... Area residents now have access to the latest ... all in a luxurious spa environment designed for relaxation ... and general dentist, designed her first Northern Westchester location, ...
... The Pew Charitable Trusts today announced that Susan G. Komen ... space in its D.C. headquarters, located at 901 E Street, ... Fenty, Pew has dedicated the vast majority of its building ... first "nonprofit village.""Susan G. Komen for the Cure(R) has been ...
... Health Plan Members Drop Coverage for Multiple Reasons; ... Necessary to Reduce Disenrollment and Improve Balance SheetORLANDO, ... behalf of ConnextionsHealth provides both good and bad ... properly managing member disenrollment delivers a significant, positive ...
Cached Medicine News:Health News:'Swipe Card, See Image': OAD Orthopaedics Improves Clinical Workflow with OrthoFlow 2Health News:Rearrangements of multifunctional genes cause cancer in children and young people 2Health News:High-Tech Meets Luxury at New Dental Practice: Introducing Westchester Smile Design 2Health News:Susan G. Komen for the Cure(R) Signs Lease at Pew's Nonprofit Village 2Health News:Susan G. Komen for the Cure(R) Signs Lease at Pew's Nonprofit Village 3Health News:Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows 2Health News:Common Approaches to Member Retention by Health Insurance Plans are Ineffective, New Study Shows 3
... generation of Urocap, features automatic ... stopping and printing. The advanced ... with superior low flow rate ... ICS nomenclature normative comparisons to ...
... Stents combine a unique polymer material that ... shape with a chemically bonded wettable solution ... is a stent that satisfies the need ... Lubri-Flex® is available in a wide variety ...
... The Pathfinder Chlamydia Culture ... reliable staining of intracellular ... reticulate bodies) in tissue ... antibody used in this ...
... a direct antigen detection system, that can use ... and monoclonal antibodies to detect RSV directly in ... and reproducibility of monoclonal antibodies with the speed ... are availalbe within 90 minutes. The Pathfinder RSV ...
Medicine Products: